According to our research report “German Pharma Sector Analysis”, Germany is one of the largest pharmaceutical markets in the world. Most of the German pharma companies are focused on research, which has led the country to become one of the most advanced pharma markets in the world. On the back of several factors like increasing prevalence of chronic and lifestyle diseases, German pharmaceutical market is projected to grow at a CAGR of around 4.8% during 2010-2012. Our report has discussed all the market drivers that are fuelling growth in this industry.
We have found that the regulatory environment standard of the country is at par with the global standards. We expect that the future investments in this sector will be dominated by investments in the R&D segment. The country is home to hundreds of small and medium sized research-based pharma firms, which are continuously involved in the development of various drugs. Although the acceptance ratio for generic drugs in Germany is quite high, there still exists a large market for branded drugs in the country. Our report has analyzed both branded and generic drugs market with their future outlook till 2012.
Our study shows that the export constitutes a large part of the total German pharmaceutical market. Export is considered to be the growth engine of German economy, which is now reviving after the global economic downturn. In future as well, the export ratio of German pharma industry is expected to increase, because of constricting domestic pharma industry. The report provides an overview on domestic consumption and export pattern along with their share in 2009 and expected share of exports in 2012.
Among the latest industry trends, we have found that the most common trend is the expansion of production facility by major pharma players. It has been seen that most of the pharma players in the country are currently reviewing their expansion strategies and planning to invest in the production facilities. In this regard, our report provides detail information on latest developments of the industry. We have also discussed the government regulations and initiatives and competitive landscape.
For more information visit: http://www.rncos.com/Report/IM253.htm |
